Vitiligo: An Update on Pathophysiology and Treatment Options

Area of Science:

• Dermatology
• Immunology
• Genetics

Background:

• Vitiligo pathophysiology is increasingly understood, involving innate immunity, oxidative stress, and melanocyte adhesion loss.
• Non-segmental vitiligo primarily results from immune-mediated melanocyte destruction by cytotoxic T cells.
• Segmental vitiligo appears to have a distinct pathogenesis, possibly a mosaic skin disorder.

Purpose of the Study:

• To clarify the underlying mechanisms of vitiligo pathogenesis.
• To review current and emerging treatment strategies for vitiligo.
• To highlight recent advancements and future directions in vitiligo research.

Main Methods:

• Review of current scientific literature on vitiligo pathophysiology and treatment.
• Analysis of genetic research findings related to vitiligo.
• Examination of recent therapeutic developments and clinical trial methodologies.

Main Results:

• Key factors in non-segmental vitiligo include innate immunity activation, inflammasome, oxidative stress, and T-cell mediated melanocyte destruction.
• Genetic studies show multi-genetic inheritance with overlap with autoimmune disorders and affected melanocyte-specific genes.
• Current treatments include topical corticosteroids, immunomodulators, UVB therapy, and pigment cell transplantation, with new targeted immunotherapies under investigation.

Conclusions:

• Understanding vitiligo pathophysiology is advancing, revealing immune-mediated destruction as a key mechanism.
• Emerging targeted immunotherapies offer potential for halting active immune pathways in vitiligo.
• Standardized clinical trials, aided by new outcome measures and biomarkers, will facilitate the development of more effective vitiligo therapies.